{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T14:02:46Z","timestamp":1770818566738,"version":"3.50.1"},"reference-count":27,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Gachon University Research Fund","award":["GCU-202410670001"],"award-info":[{"award-number":["GCU-202410670001"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: The increasing number of patients with prostate cancer receiving long-term androgen deprivation therapy (ADT) underscores the importance of maintaining quality of life during treatment. Lower urinary tract symptoms (LUTS), influenced by prostate size, represent significant determinants of quality of life in this population. This study aimed to investigate the impact of ADT on LUTS in patients with prostate cancer, particularly focusing on how ADT, which reduces prostate volume (PV), affects quality of life, and to identify factors influencing changes in LUTS. Materials and Methods: The study included 104 patients with prostate cancer undergoing ADT. Changes in the International Prostate Symptom Score (IPSS), PV, maximal uroflow rate (Qmax), post-void residual urine volume (RU), and prostate-specific antigen (PSA) levels were compared before treatment initiation and at 12 and 24 weeks after treatment. Association between these variables and patient age, body mass index (BMI), Gleason score (GS), and T stage were also assessed. Results: After 12 and 24 weeks of ADT, prostate size decreased by 16.69 cm3 (32.03%) and 25.36 cm3 (48.68%), respectively, with PSA levels decreasing by 7.63 ng\/mL and 22.03 ng\/mL. Qmax improved by 3.19 mL\/s and 5.57 mL\/s, and RU decreased by 42.31 mL and 60.68 mL, respectively (p &lt; 0.001). The IPSS decreased by 13.09 and 14.69 points at 12 and 24 weeks, respectively (p &lt; 0.001). Notably, patients with moderate-to-severe LUTS (baseline IPSS \u2265 8) showed a significantly greater reduction in IPSS (p &lt; 0.001). Additionally, patient age and PSA levels were significantly associated with changes in Qmax (p &lt; 0.001). Conclusions: ADT demonstrated a positive effect on LUTS improvement in patients with prostate cancer, particularly among those with moderate-to-severe LUTS, elevated PSA levels, or older age.<\/jats:p>","DOI":"10.3390\/medicina62020359","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T11:13:15Z","timestamp":1770808395000},"page":"359","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Androgen Deprivation Therapy on Lower Urinary Tract Symptoms in Patients with Prostate Cancer"],"prefix":"10.3390","volume":"62","author":[{"given":"Tae Young","family":"Park","sequence":"first","affiliation":[{"name":"Gil Medical Center, Department of Urology, College of Medicine, Gachon University, Incheon 21936, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4143-7383","authenticated-orcid":false,"given":"Sung Ryul","family":"Shim","sequence":"additional","affiliation":[{"name":"Department of Biomedical Informatics, College of Medicine, Konyang University, Daejeon 35365, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3901-0295","authenticated-orcid":false,"given":"Chang Hee","family":"Kim","sequence":"additional","affiliation":[{"name":"Gil Medical Center, Department of Urology, College of Medicine, Gachon University, Incheon 21936, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"ref_1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","first-page":"409","article-title":"Cancer treatment and survivorship statistics, 2022","volume":"72","author":"Miller","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","unstructured":"Mottet, N., Cornford, P., van den Bergh, R.C.N., Briers, E., Eberli, D., De Santis, M., Gillessen, S., Grummet, J., Henry, A.M., and van der Kwast, T.H. (2024). EAU Guidelines on Prostate Cancer 2024, European Association of Urology Guidelines Office. Available online: https:\/\/uroweb.org\/guidelines\/prostate-cancer."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Galvez, A., Puri, D., Tran, E., Zaila Ardines, K., and Santiago-Lastra, Y. (2025). Navigating Pathways in Prostate Cancer Survivorship: A Comprehensive Review of Challenges, Interventions, and Long-Term Outcomes. Uro, 5.","DOI":"10.3390\/uro5020010"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Shin, D., Shim, S.R., and Kim, C.H. (2020). Changes in Beck Depression Inventory scores in prostate cancer patients undergoing androgen deprivation therapy or prostatectomy. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0234264"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Song, W., Kim, J.-S., and Ko, K.J. (2023). Baseline Lower Urinary Tract Symptoms and Sexual Dysfunction in Men with Newly Diagnosed Localized Prostate Cancer. J. Clin. Med., 12.","DOI":"10.3390\/jcm12134462"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13014-024-02563-x","article-title":"Analysis of urinary function and prostate volume changes in localized prostate cancer patients treated with carbon-ion radiotherapy; a prospective study","volume":"19","author":"Miyazawa","year":"2024","journal-title":"Radiat. Oncol."},{"key":"ref_8","unstructured":"Gravas, S., Cornu, J.N., Gacci, M., Gratzke, C., Herrmann, T.R.W., Mamoulakis, C., Rieken, M., Speakman, M.J., and Tikkinen, K.A.O. (2024). EAU Guidelines on Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS), incl. Benign Prostatic Obstruction (BPO), European Association of Urology Guidelines Office. Available online: https:\/\/uroweb.org\/guidelines\/non-neurogenic-male-luts."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"261","DOI":"10.5213\/inj.2010.14.4.261","article-title":"Analysis of initial baseline clinical parameters and treatment strategy associated with medication failure in the treatment of benign prostatic hyperplasia in Korea","volume":"14","author":"Choi","year":"2010","journal-title":"Int. Neurourol. J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"EVIDoa2300018","DOI":"10.1056\/EVIDoa2300018","article-title":"Patient-Reported Outcomes 12 Years after Localized Prostate Cancer Treatment","volume":"2","author":"Donovan","year":"2023","journal-title":"NEJM Evid."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"764","DOI":"10.21037\/tau-2025-12","article-title":"Tracking and analysis of benign prostatic hyperplasia and prostate cancer burden globally: 1990\u20132021 epidemiological trends","volume":"14","author":"Mo","year":"2025","journal-title":"Transl. Androl. Urol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.5213\/inj.2142112.056","article-title":"The Prevalence of Lower Urinary Tract Symptoms and Overactive Bladder in South Korea: A Cross-Sectional, Population-Based Study","volume":"26","author":"Kim","year":"2022","journal-title":"Int. Neurourol. J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"120","DOI":"10.5213\/inj.2015.19.2.120","article-title":"The Impact of Lower Urinary Tract Symptoms on Quality of Life, Work Productivity, Depressive Symptoms, and Sexuality in Korean Men Aged 40 Years and Older: A Population-Based Survey","volume":"19","author":"Kim","year":"2015","journal-title":"Int. Neurourol. J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1093\/jrr\/rrae056","article-title":"Impact of neoadjuvant androgen deprivation therapy on toxicity in intensity modulated radiation therapy for prostate cancer","volume":"65","author":"Serizawa","year":"2024","journal-title":"J. Radiat. Res."},{"key":"ref_15","first-page":"141","article-title":"Effect on Prostate Volume Following Neoadjuvant Treatment with an Androgen Receptor Inhibitor Monotherapy Versus Castration Plus an Androgen Receptor Inhibitor in Prostate Cancer Patients Intended for Curative Radiation Therapy: A Randomised Study","volume":"8","author":"Majumder","year":"2018","journal-title":"Mol. Clin. Oncol."},{"key":"ref_16","first-page":"2079","article-title":"Incidence of the adverse effects of androgen deprivation therapy for prostate cancer: A systematic literature review","volume":"28","author":"Edmunds","year":"2020","journal-title":"Support. Care Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/luts.12114","article-title":"Degarelix Versus Goserelin Plus Bicalutamide in the Short-Term Relief of Lower Urinary Tract Symptoms in Prostate Cancer Patients: Results of a Pooled Analysis","volume":"9","author":"Mason","year":"2017","journal-title":"LUTS Low. Urin. Tract Symptoms"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3892\/etm.2020.8851","article-title":"Efficacy and Safety of Dutasteride Compared with Finasteride in Treating Males with Benign Prostatic Hyperplasia: A Meta-Analysis of Randomized Controlled Trials","volume":"20","author":"Zhou","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"342","DOI":"10.5213\/inj.1632628.314","article-title":"The influence of androgen deprivation therapy on prostate size and voiding symptoms in prostate cancer patients in Korea","volume":"20","author":"Choi","year":"2016","journal-title":"Int. Neurourol. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/JU.0000000000003698","article-title":"Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia (BPH): AUA Guideline Amendment 2023","volume":"211","author":"Sandhu","year":"2024","journal-title":"J. Urol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"129","DOI":"10.5534\/wjmh.240306","article-title":"Development of a new diagnostic tool (LUTS\/BPH Score) for male lower urinary tract symptoms due to benign prostatic hyperplasia","volume":"44","author":"Jeh","year":"2026","journal-title":"World J. Mens Health"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Topazio, L., Perugia, C., De Nunzio, C., Gaziev, G., Iacovelli, V., Bianchi, D., Vespasiani, G., and Finazzi Agr\u00f2, E. (2018). Intravescical Prostatic Protrusion Is a Predictor of Alpha Blockers Response: Results from an Observational Study. BMC Urol., 18.","DOI":"10.1186\/s12894-018-0320-0"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/bco2.292","article-title":"Triptorelin therapy for lower urinary tract symptoms (LUTS) in prostate cancer patients: A systematic meta-analysis","volume":"5","author":"Barrett","year":"2023","journal-title":"BJUI Compass"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ucl.2025.07.003","article-title":"Benign Prostatic Hyperplasia Procedures in Patients with Prostate Cancer:: What Do We Know?","volume":"52","author":"Scovell","year":"2025","journal-title":"Urol. Clin. N. Am."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.aju.2017.08.005","article-title":"Can androgen-deprivation therapy obviate the need of channel transurethral resection of the prostate in advanced prostate cancer with urinary retention? A prospective study","volume":"15","author":"Sood","year":"2017","journal-title":"Arab J. Urol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"18535","DOI":"10.1038\/s41598-022-21963-1","article-title":"Clinical significance of prostate volume and testosterone reduction on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy","volume":"12","author":"Bang","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_27","first-page":"387","article-title":"How does symptom severity impact clinical outcomes of men with lower urinary tract symptoms after holmium laser enucleation or transurethral resection of the prostate?","volume":"75","author":"Tamalunas","year":"2022","journal-title":"Cent. Eur. J. Urol."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/2\/359\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T11:59:36Z","timestamp":1770811176000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/2\/359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":27,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["medicina62020359"],"URL":"https:\/\/doi.org\/10.3390\/medicina62020359","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]}}}